This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. ATNM, AADI, NBRV, EGRX, PYRGF, NNVC, TAOX, IBIO, MTNB, and AEONShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Actinium Pharmaceuticals (ATNM), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), NanoViricides (NNVC), Synaptogenix (TAOX), iBio (IBIO), Matinas Biopharma (MTNB), and AEON Biopharma (AEON). Gemphire Therapeutics vs. Its Competitors Actinium Pharmaceuticals Aadi Bioscience Nabriva Therapeutics Eagle Pharmaceuticals PyroGenesis Canada NanoViricides Synaptogenix iBio Matinas Biopharma AEON Biopharma Actinium Pharmaceuticals (NYSE:ATNM) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Do analysts rate ATNM or GEMP? Actinium Pharmaceuticals presently has a consensus target price of $4.50, suggesting a potential upside of 195.08%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Actinium Pharmaceuticals is more favorable than Gemphire Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemphire Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, ATNM or GEMP? Actinium Pharmaceuticals has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500. Does the media refer more to ATNM or GEMP? In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Gemphire Therapeutics'average media sentiment score. Company Overall Sentiment Actinium Pharmaceuticals Neutral Gemphire Therapeutics Neutral Which has preferable earnings and valuation, ATNM or GEMP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium PharmaceuticalsN/AN/A-$48.82M-$1.31-1.16Gemphire TherapeuticsN/AN/A-$23.64MN/AN/A Do insiders & institutionals have more ownership in ATNM or GEMP? 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are held by institutional investors. 6.0% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ATNM or GEMP more profitable? Actinium Pharmaceuticals' return on equity of -100.85% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Gemphire Therapeutics N/A -419.70%-173.05% SummaryActinium Pharmaceuticals beats Gemphire Therapeutics on 6 of the 9 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.06M$1.02B$9.08B$10.59BDividend YieldN/A4.84%5.69%4.71%P/E RatioN/A1.2686.0127.55Price / SalesN/A141.72539.22204.66Price / CashN/A17.6437.9261.55Price / Book2.007.3612.946.77Net Income-$23.64M-$7.88M$3.30B$275.88M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$1.08+1.9%N/A-60.7%$16.06MN/A0.009ATNMActinium Pharmaceuticals1.9907 of 5 stars$1.60-1.2%$4.50+181.3%-5.5%$49.91MN/A-1.1530AADIAadi BioscienceN/A$1.92-1.0%N/A+13.8%$47.42M$25.07M-0.8440NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070EGRXEagle Pharmaceuticals1.4492 of 5 stars$2.70-4.4%N/A+445.5%$35.07M$257.55M0.00100Gap DownPYRGFPyroGenesis CanadaN/A$0.17+1.3%N/A-69.1%$31.47M$9.14M-2.8390High Trading VolumeNNVCNanoViricides0.4325 of 5 stars$1.43+0.7%N/A+0.7%$22.98MN/A-1.9920Gap UpTAOXSynaptogenix0.058 of 5 stars$6.55+4.3%N/AN/A$21.90MN/A-0.324News CoverageAnalyst ForecastIBIOiBio2.3658 of 5 stars$0.83-1.0%$5.00+504.0%-67.3%$16.27M$400K-0.48100MTNBMatinas BiopharmaN/A$1.90-0.3%N/AN/A$9.64MN/A-0.3930Gap DownAEONAEON Biopharma1.0123 of 5 stars$0.81-1.3%$360.00+44,399.4%-99.1%$9.42MN/A4.495Analyst ForecastGap Up Related Companies and Tools Related Companies Actinium Pharmaceuticals Competitors Aadi Bioscience Competitors Nabriva Therapeutics Competitors Eagle Pharmaceuticals Competitors PyroGenesis Canada Competitors NanoViricides Competitors Synaptogenix Competitors iBio Competitors Matinas Biopharma Competitors AEON Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
